Home Cart Sign in  
Chemical Structure| 937272-79-2 Chemical Structure| 937272-79-2

Structure of Pacritinib
CAS No.: 937272-79-2

Chemical Structure| 937272-79-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50 = 23 nM) and the JAK2V617F mutant (IC50 = 19 nM), and also inhibits FLT3 (IC50 = 22 nM) and its mutant FLT3D835Y (IC50 = 6 nM).

Synonyms: SB1518

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pacritinib

CAS No. :937272-79-2
Formula : C28H32N4O3
M.W : 472.58
SMILES Code : C1(OCCN2CCCC2)=CC=C(/N=C3NC4=CC=N\3)C=C1COC/C=C/COCC5=CC4=CC=C5
Synonyms :
SB1518
MDL No. :MFCD22572772
InChI Key :HWXVIOGONBBTBY-ONEGZZNKSA-N
Pubchem ID :46216796

Safety of Pacritinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Related Pathways of Pacritinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • JAK3

    JAK3, IC50:520 nM

  • Tyk2

    TYK2, IC50:50 nM

  • JAK2

    JAK2 (V617F), IC50:19 nM

    JAK2, IC50:23 nM

  • FLT3

    FLT3 (D835Y), IC50:6 nM

    FLT3, IC50:22 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Hepatic Stellate Cells (HSCs) 1 μm 24 h Pacritinib reduced gene expression of fibrosis markers and decreased proliferation and contraction of HSCs. PMC10026969
breast cancer cell lines 50 mg/kg various times Pacritinib reduced cell viability and promoted apoptosis in breast cancer cells. PMC11533721

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CCl4 and ethanol-induced liver fibrosis Oral 300 mg/kg three times per week for 3 weeks Pacritinib treatment reduced liver fibrosis and liver injury. PMC10026969
Mice TNBC PDX model Oral 50 mg/kg twice daily for 5 days/week until study termination Pacritinib effectively suppressed tumor growth in vivo. PMC11533721

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02251821 Primary Myelofibrosis ... More >> Secondary Myelofibrosis Less << Phase 2 Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Rachel B. Salit    206-667-1317    rsalit@fredhutch.org    Principal Investigator: Rachel B. Salit Less <<
NCT02823171 Healthy Phase 1 Completed - United States, Indiana ... More >> Covance Clinical Research Unit Inc. Evansville, Indiana, United States, 47710 Less <<
NCT02342353 Non-Small Cell Lung Cancer ... More >> Nonsmall Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Less << Phase 1 Terminated(Drug shortage) - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT02807207 Healthy Subjects Phase 1 Completed - United States, Indiana ... More >> Covance Clinical Research Unit Inc. Evansville, Indiana, United States, 47710 Less <<
NCT02584777 Primary Myelofibrosis Phase 2 Withdrawn August 2020 -
NCT02808455 Healthy Subjects Phase 1 Completed - United States, Florida ... More >> Covance Clinical Research Unit Daytona Beach, Florida, United States, 32117 Less <<
NCT02891603 Graft Vs Host Disease ... More >> GVHD Less << Phase 1 Phase 2 Recruiting June 2020 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Principal Investigator: Joseph Pidala, M.D.          Sub-Investigator: Melissa Alsina, M.D.          Sub-Investigator: Marco Davila, M.D., Ph.D.          Sub-Investigator: Linda Kelley, Ph.D.          Sub-Investigator: Farhad Khimani, M.D.          Sub-Investigator: Frederick Locke, M.D.          Sub-Investigator: Asmita Mishra, M.D.          Sub-Investigator: Taiga Nishihori, M.D.          Sub-Investigator: Jose Ochoa-Bayona, M.D.          Sub-Investigator: Lia Perez, M.D.          Sub-Investigator: Hugo Fernandez, M.D, Less <<
NCT02469415 Leukemia Phase 2 Terminated(FDA Clinical Hold) - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02323607 Recurrent Adult Acute Myeloid ... More >>Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 1 Suspended(internal data analys... More >>is) Less << September 30, 2018 United States, Ohio ... More >> Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT02469415 - Terminated(FDA Clinical Hold) - -
NCT02410551 - Terminated - -
NCT02410551 Myeloproliferative Diseases Phase 2 Terminated - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02807077 Myelofibrosis PHASE1 COMPLETED 2025-07-15 APEX GmbH, Munich, D-81241, Ge... More >>rmany|Republican Clinical Hospital, Chisinau, MD-2025, Moldova, Republic of|Carol Davila Nephrology Hospital Bucharest, Bucharest, Romania Less <<
NCT02277093 Colorectal Cancer PHASE2 TERMINATED 2016-10-27 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT02564536 Chronic Myelomonocytic Leukemi... More >>a Juvenile Myelomonocytic Leukemia Atypical Chronic Myeloid Leukemia Myeloproliferative Neoplasm Myelodysplastic Syndromes Myelofibrosis Less << Phase 1 Withdrawn(Lack of funding foll... More >>owing full FDA clinical hold) Less << June 30, 2020 -
NCT03165734 Primary Myelofibrosis ... More >> Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << Phase 2 Recruiting March 1, 2019 -
NCT03601819 Lymphoma, T-Cell, Cutaneous|Ly... More >>mphoma, T-Cell, Peripheral|Chronic Lymphocytic Leukemia|Lymphoproliferative Disorders|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma Less << PHASE1 TERMINATED 2020-07-17 University of Michigan Rogel C... More >>ancer Center, Ann Arbor, Michigan, 48109, United States Less <<
NCT01773187 Primary Myelofibrosis ... More >> Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << Phase 3 Terminated - -
NCT02807051 Drug Interaction Study Phase 1 Completed - United States, Florida ... More >> Covance Clinical Research Unit Daytona Beach, Florida, United States, 32117 Less <<
NCT02055781 Primary Myelofibrosis ... More >> Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << Phase 3 Terminated - -
NCT02277093 Colorectal Cancer PHASE2 TERMINATED 2016-10-27 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT02807116 Healthy Subjects Phase 1 Completed - United States, Florida ... More >> Covance Clinical Research Unit Daytona Beach, Florida, United States, 32117 Less <<
NCT02677948 Chronic Lymphocytic Leukemia ... More >> Lymphoma, Small Lymphocytic Less << Phase 1 Phase 2 Withdrawn(FDA has placed all t... More >>rials involving Pacritinib on Full Clinical Hold) Less << October 2018 United States, Michigan ... More >> University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT02532010 Acute Myeloid Leukemia (AML) Phase 2 Terminated(The study was put o... More >>n clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.) Less << - United States, New York ... More >> Weill Cornell Medical College New York, New York, United States, 10021 Less <<
NCT03645824 Myelofibrosis PHASE2 ACTIVE_NOT_RECRUITING 2025-02-27 BE-Antwerpen-ZNASTUIVENBERG, A... More >>ntwerpen, Belgium|BE-Gent-UZGENT, Gent, Belgium|BE-Leuven-UZLEUVEN, Leuven, Belgium|BE-Roeselare-AZDELTA, Roeselare, Belgium|NL-Amsterdam-AMC, Amsterdam, Netherlands|NL-Amsterdam-VUMC, Amsterdam, Netherlands|NL-Groningen-UMCG, Groningen, Netherlands|NL-Maastricht-MUMC, Maastricht, Netherlands|NL-Nijmegen-RADBOUDUMC, Nijmegen, Netherlands|NL-Rotterdam-EMCDANIEL, Rotterdam, Netherlands|NL-Rotterdam-ERASMUSMC, Rotterdam, Netherlands|NL-Utrecht-UMCUTRECHT, Utrecht, Netherlands Less <<
NCT02765724 Myelofibrosis PHASE1 COMPLETED 2025-06-15 APEX GmbH, Munich, D-81241, Ge... More >>rmany|Republican Clinical Hospital, Chisinau, MD-2025, Moldova, Republic of Less <<
NCT02532010 - Terminated(The study was put o... More >>n clinical hold by the sponsor since Feb 9th 2016, and was later decided not to re-open due to financial constraints.) Less << - -
NCT02803762 Healthy PHASE1 COMPLETED 2025-10-14 QPS Netherlands B.V., Groninge... More >>n, 9713 GZ, Netherlands Less <<
NCT05531786 Graft vs Host Disease PHASE1|PHASE2 RECRUITING 2025-07-22 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT04884191 Primary Myelofibrosis|Post-Pol... More >>ycythemia Vera Myelofibrosis|Post- Essential Thrombocythemia Myelofibrosis Less << PHASE2 COMPLETED 2019-09-04 Mayo Clinic Hospital, Phoenix,... More >> Arizona, 85054, United States|City of Hope, Duarte, California, 91010, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, 90095, United States|Stanford Cancer Institute, Stanford, California, 94305, United States|Yale School of Medicine, New Haven, Connecticut, 06520, United States|Medical Faculty Associates, Inc., Washington, District of Columbia, 20037, United States|Florida Cancer Specialists & Research Institute, Fort Myers, Florida, 33901, United States|Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists & Research Institute, West Palm Beach, Florida, 33401, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, United States|The University of Chicago Medical Center, Chicago, Illinois, 60637, United States|University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|Ochsner Medical Center, New Orleans, Louisiana, 70121, United States|Saint Agnes Hospital, Baltimore, Maryland, 21229, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Weill Cornell Medical College, New York, New York, 10021, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Columbia University, New York, New York, 10032, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|University of Rochester, Rochester, New York, 14642, United States|Duke University Hospital, Durham, North Carolina, 27710, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Texas Health Science Center at San Antonio School of Medicine, San Antonio, Texas, 78229, United States|University of Utah School of Medicine, Salt Lake City, Utah, 84112, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|CHU Hopital Sud, Amiens, 80054, France|Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez, Lille Cedex, 59037, France|CHU de Nimes - Hopital Universitaire Caremeau, N?mes, 30029, France|H?pital Saint-Louis, Paris, 75010, France|CHU Hopitaux de Bordeaux - H?pital Haut-Lévêque, Pessac, 33604, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, 69495, France|Centre Hospitalier Universitaire de Toulouse- H?pital Purpan, Toulouse Cedex, 31059, France|SE AOK I. sx. Belgyogyaszati Klinika, Budapest, 1083, Hungary|Debreceni Egyetem Klinikai K?zpont, Debrecen, 4032, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, 7400, Hungary|Azienda Ospedaliero-Universitaria Careggi, Firenze, 50134, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura Dei Tumori, Meldola, 47014, Italy|ASST Monza - Ospedale San Gerardo, Monza, 20900, Italy|Yeungnam University Medical Center, Daegu, 42415, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Hospital del Mar, Barcelona, 08003, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Clínica Universidad de Navarra, Pamplona, 31008, Spain|Skane University Hospital Lund, Lund, 22185, Sweden|Orebro University Hospital, ?rebro, 70185, Sweden|Beatson West of Scotland Cancer Center, Glasgow, G12 0YN, United Kingdom|Barts Health NHS Trust - The Royal London Hospital, London, E1 2ES, United Kingdom|Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London, SE1 9RT, United Kingdom|Imperial College Healthcare NHS Trust - Hammersmith Hospital, London, W12 0HS, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, OX3 7LE, United Kingdom Less <<
NCT04635059 Prostate Cancer PHASE2 TERMINATED 2024-10-27 Froedtert & the Medical Colleg... More >>e of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less <<
NCT06052618 KSHV Inflammatory Cytokine Syn... More >>drome (KICS)|Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease Less << PHASE2 RECRUITING 2034-01-01 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT04520269 Breast Cancer PHASE1|PHASE2 UNKNOWN 2025-07-23 National University Hospital, ... More >>Singapore, Singapore Less <<
NCT01436084 Leukemia PHASE2 TERMINATED 2025-06-13 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT01263899 Hodgkin Lymphoma|Mantle Cell L... More >>ymphoma|Indolent Lymphoma Less << PHASE2 COMPLETED 2025-02-12 University of Nebraska Medical... More >> Center, Omaha, Nebraska, 68198, United States|Weill Medical College of Cornell, New York, New York, 10021, United States|University of Rochester James P. Wilmot Cancer Center, Rochester, New York, 14642, United States|MD Anderson Cancer Canter, Houston, Texas, 77030, United States|University of British Columbia, Vancouver, British Columbia, V5Z 4E6, Canada Less <<
NCT00719836 Acute Myelogenous Leukemia|Chr... More >>onic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Myelofibrosis Less << PHASE1|PHASE2 COMPLETED 2025-01-12 The University of Chicago Hosp... More >>itals, Chicago, Illinois, 60637, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Fred Hutchinson Cancer Center, Seattle, Washington, 98109, United States Less <<
NCT00741871 Lymphoma, Malignant|Hodgkin's ... More >>Lymphoma|B Cell Lymphoma Less << PHASE1 COMPLETED 2025-10-11 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<
NCT06538181 E1 Ubiqutin-activating Enzyme,... More >> X-linked, Autoinflammatory, Somatic Syndrome|VEXAS|Vexas Syndrome Less << PHASE1 NOT_YET_RECRUITING 2029-03-31 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT04858256 T-Cell Neoplasm|Lymphoprolifer... More >>ative Disorders Less << PHASE2 RECRUITING 2025-11-28 City of Hope, Duarte, Californ... More >>ia, 91010, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, 48109, United States|Duke Cancer Institute, Durham, North Carolina, 27710, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43202, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States Less <<
NCT00745550 Myelofibrosis|Myeloproliferati... More >>ve Disorders|Polycythemia Vera|Essential Thrombocythemia Less << PHASE1|PHASE2 COMPLETED 2025-01-12 Mayo Clinic, Scottsdale, Arizo... More >>na, 85259, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3002, Australia|Royal Melbourne Hospital, Melbourne, Victoria, 3050, Australia|Royal Adelaide Hospital, Adelaide, 5000, Australia Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.12mL

0.42mL

0.21mL

10.58mL

2.12mL

1.06mL

21.16mL

4.23mL

2.12mL

References

 

Historical Records

Categories